Ypsomed expands digital offering with S3 Connected Health

Ypsomed will expand its offering of digital health solutions in the future in collaboration with S3 Connected Health. S3 Connected Health, headquartered in Dublin, Ireland, is a specialist digital health partner for life sciences companies.

The offering will allow Ypsomed’s biopharma customers to launch therapy-specific digital patient solutions. Thus people suffering from acute and chronic diseases can be fully supported in their medical management and their treatment outcome can be enhanced.

Digital health solutions play a critical role in how well patients with acute and chronic illnesses manage their medical care. To further this growth, Ypsomed has partnered with S3 Connected Health to create an extensible platform for building specialized solutions that support and guide patients throughout their therapy. SmartPilots for Ypsomed’s connected injection devices such as the YpsoMate are pre-integrated into the platform. The platform is highly versatile and quick to adapt to any disease area and use case – always with the aim of providing added value to patients.

Ulrike Bauer, Chief Business Officer, Delivery Systems, said: “The new platform will enable our pharma and biotech customers to rapidly launch integrated device and digital health solutions that further improve medical outcomes and quality of life for their patients. This new product complements our existing product portfolio and partnerships in the connected devices and digital health space. This will help us strengthen our position in this segment and provide the best possible value to our customers.”

Low complexity with high added value

Ypsomed’s offering is powered by S3 Connected Health’s Efinial Platform, the most comprehensive platform for life science companies to build regulated digital health solutions. Efinial is designed to empower digital health applications and use cases by encoding over 20 years of best practice experience in the delivery of digital health at scale. Since its launch, Efinial has established itself as the leading platform for life science companies.

The new platform offering includes a patient application, a diagnostic system, a patient support portal and analytical dashboard with real-time access to anonymized data. Along with pre-integration to Ypsomed’s device portfolio, the platform offers a range of features around self-injection, incorporating behavioral science mechanisms to ensure a high level of interaction, and application to users’ needs. personalizes.

Jim O’Donoghue, President of S3 Connected Health, said: “We look forward to collaborating closely with Ypsomed to achieve our shared vision of improving patients’ lives. Our Efinial platform and deep expertise in building and operating regulated digital health solutions fit perfectly with Ypsomed’s drive for innovation and the highest quality.

The new product offering will be marketed through Ypsomed and offered in association with S3 Connected Health for customers to optimize for their specific use cases and service of the brand.